P031 Assessing the safety and efficacy of JAK inhibitors in inflammatory arthritis

Abstract

Abstract Background/Aims JAK inhibitors were recently licensed in the UK and have been shown to be efficacious in refractory moderate to severe rheumatoid arthritis and psoriatic arthritis. We aim to assess their efficacy and safety in use in clinical practice in NHS Tayside. Additionally, there have been several emerging safety concerns, particularly regarding infections and venous thromboembolism risk. Methods This project was an observational retrospective case note review of 130 patients. We assessed JAK-inhibitor efficacy via mean change in DAS28 and number of tender and swollen joints at 6 months after initiating therapy. Additionally, 6-month and 2-year drug survival rates were calculated. The presence of adverse events was evaluated. Results At 6 months JAK inhibitor therapy produced a mean reduction in DAS28 of 2.04 (p = 0.096) and a mean reduction in number of swollen joints of 3.72 (p = 0.002). Drug survival was 81.42% at 6-months and 51.25% at 24-months. Non-smokers, those with BMI <30, biologic naïve patients and those prescribed a concomitant cDMARD all achieved a greater reduction in DAS28. 53 patients (40.77%) experienced an adverse event, including venous thromboembolism, acute diverticulitis and herpes zoster reactivation. In addition to these, 40.91% of patients experienced dyslipidaemia. Conclusion JAK-inhibitors are efficacious in controlling active disease in inflammatory arthritis, however, are better suited to some patients over others based on emergency concerns about side effect profiles. Longer follow up is needed to assess long term efficacy. Disclosure I. Smedley: None.